Default Category
-
Deferred Tax Assets in Basel III: Lessons from Japan, Teaching Note
Hawkins, David F.; Ramanna, KarthikTeaching Note HBS-112114-EAccounting and ControlTeaching Note for 111076.Starting at €0.00
-
Kanebo Ltd. (A)
Hawkins, David F.; Srinivasan, Suraj; Kanno, Akiko; Gomez, LizzieCase HBS-111037-EAccounting and ControlThis case speculates how Japanese companies might implement IFRS, with particular emphasis on consolidation accounting.Starting at €8.20
-
Kanebo Ltd. (B)
Hawkins, David F.; Srinivasan, Suraj; Kanno, AkikoCase HBS-111038-EAccounting and ControlFinancial statements before and after restatement following revelation of fraud.Starting at €5.74
-
Kanebo Ltd. (C)
Hawkins, David F.; Srinivasan, Suraj; Kanno, AkikoCase HBS-111068-EAccounting and ControlThe exposure of the Kanebo Ltd. fraud raises questions of Japan's preparedness to adopt International Financial Reporting Standards.Starting at €5.74
-
Deferred Tax Assets in Basel III: Lessons from Japan
Hawkins, David F.; Ramanna, Karthik; Sato, Nobuo; Yamazaki, MayukaCase HBS-111076-EAccounting and ControlIn a controversial decision, the Bank for International Settlements includes deferred tax assets as part of a bank's core capital.Starting at €8.20
-
Kanebo Ltd. (A), (B), and (C), Teaching Note
Hawkins, David F.; Srinivasan, SurajTeaching Note HBS-112039-EAccounting and ControlTeaching Note for 111-037, 111-038, and 111-068.Starting at €0.00
-
Catalys Pacific
Krieger, Joshua LevCase HBS-821035-EKnowledge and CommunicationIn 2019, BT Slingsby founds Catalys Pacific, the first biotech "venture creation" fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After examining hundreds of potential investment opportunities, his team must decide which deals to pursue first. How can Catalys Pacific establish a positive investment track record whi...Starting at €8.20